''Tup'poncd'by'u.S.P.H.S. grants CA-06551, CA-ease, 23 Down's syndrome, 5 and lepromatous 08069, CA-06927, and RR-05539 from the National leprosy 0 ) are associated with persistent Aus- > -"•'-" These patients are distinguished in other ways by atypical responses to other diseases. They have a high frequency of chronic respiratory and intestinal infections,-1 some abnormalities in their immunoglobulin levels, 24 and a 40-to 50-fold increased incidence of acute leukemia when compared with the normal population.- 0 We previously reported the very high frequency of Australia antigen in patients with Down's syndrome compared with other mentally retarded individuals from the same large institutions.
5 '-' 0 It was the further investigation of these patients that led to the observations suggesting that Australia antigen might be a hepatitis virus. Evidence of hepatitis was barely detectable, with minimally elevated serum glutamic pyruvic transaminase (SGPT) levels being the only consistent finding.-0 Various degrees of inflammatory changes were seen in the liver biopsy specimens. Since tin's appeared to represent an atypical response to virus infection, we considered it important to characterize differences in hepatic function between patients with Down's syndrome with and without Australia antigen in their blood, in comparison with appropriate controls. Subsequent papers will present detailed data on hepatic histology, and additional findings related to the immunologic capabilities of these patients.
Materials and Methods
Patients were selected from 257 patients with Down's syndrome who were tested for Australia antigen in their blood at New Lisbon State School, New Lisbon, New Jersey, and at Pennhurst State School and Hospital, Spring City, Pennsylvania. Seventy-five were found to have Australia antigen (41 at New Lisbon and 34 at Pennhurst). Forty-three of these patients have now been followed for periods of 2 to 5 yr. Twenty-four were admitted to our Clinical Research Unit for this investigation. Twenty-four other residents with Down's syndrome who did not have Australia antigen were matched for sex, age (within 4 yr.), race, and institution, and admitted for control observations. Twenty-one other mentally retarded patients without Down's syndrome from the same institutions were matched by age, race, institution, and sex with the same number of Down's syndrome pairs. All patients had been tested repeatedly over a 2-to 5-yr. period, and were retested for Australia antigen by double immunodiffusion to confirm the presence or absence of Au(l) .
10 SGPT was assayed on nine or more different blood samples from each patient by the method of Wroblewski and LaDue.'' 2 The first nine samples obtained over a 3-week period were used for purposes of statistical analysis. The following studies relating to hepatic function were performed in the clinical laboratory of Jeanes Hospital, Philadelphia: thymol turbidity, cephalin flocculation, serum glutamic oxalacetic transaminase (SCOT), alkaline phosphatase, prothrombin time, serum bilirubin (total and direct), and total serum protein with electrophoresis on cellulose acetate. Each study was performed three times for each patient (once weekly), and the median value for each patient was used in the analysis of data. These data are recorded in the appendix. Bromsulphalein (BSP) excretion (45 min. after intravenous injection of 5 mg. per kg. body weight) was determined once for each patient. pair signed ranks test, and the chi-square test.
Results
All 43 patients with Down's syndrome, in whom Australia antigen was detected on the first testing, and who were tested periodically by our laboratory, had persistent antigen for the 2 to 5 yr. during which they were followed (Table 1) . This persistence is significantly different from the behavior of the antigen in otherwise normal people who develop acute hepatitis, and is significantly greater than that found in patients with leukemia and Australia antigen, in whom relatively long persistence has also been demonstrated.
Significant differences in SGPT levels were found between patients with Down's syndrome with Australia antigen and the other groups, confirming our previous studies. 26 We now report that this enzyme elevation is not an isolated phenomenon. The current study also demonstrates significant differences in SGOT, cephalin flocculation, thymol turbidity, total protein, serum albumin, and BSP retention between patients with Down's syndrome with and without | N = number of pairs; T = smaller sum of ranks; P = probability of being wrong in rejecting null hypothesis; N.S. = not significant. f N = 9 ; x = \\p = 0.02. J N = 10; x = l-p = 0.011.
Au(l) ( Table 2 ). With the exception of BSP retention (p = 0.084) and SGOT, similar differences were seen between patients with Down's syndrome with Au(l) and mentally retarded patients with diagnoses other than Down's syndrome. One of the mentally retarded control patients was found to have acute hepatitis on liver biopsy but no symptoms or physical findings of the disease. If this patient is excluded from the calculation, significant differences in SGOT and BSP are also found. No differences were found between the groups with respect to serum bilirubin, prothrombin time, or serum alkaline phosphatase. Table 3 is a list of the median values of results of hepatic function studies for each patient group. They generally fall within the usual "normal" range used in clinical laboratories. The findings in the patients with Down's syndrome with Au(l) are compared with the other groups for each test. The differences are small, even in those tests in which statistical significance was demonstrated. A plus (+) indicates that this test in these patients is farther in the direction of abnormality (i.e., higher for SGPT, lower for serum protein, etc.) than the results in the control group with which it is compared. A minus (-) indicates that it is "more normal" than the control. A zero (0) indicates that it is the same in the two groups compared. Application of the sign test to these data shows that these hepatic function tests are in the direction of abnormality in the patients with Down's syndrome with Au(l) , and that these findings are not due to distribution because of multiple significance testing.
The flocculation and turbidity tests reflect an imbalance in the interaction of factors found in serum. 33 Normal gamma globulin has flocculating activity, and this increases in hepatic parenchymal damage. Albumin and alpha-1 globulin are stabilizing proteins. Some of this antiflocculating capacity is lost in damage to the liver cells. Serum lipoproteins (phospholipids) also influence the thymol turbidity test. The low serum albumin may be partly responsible for the differences in cephalin flocculation and thymol turbidity, but there are no differences in the other stabilizing protein, alpha-1 globulin (Table 4) . Gamma globu- lin is significantly elevated in patients with Down's syndrome (Table 4) , as has been reported previously, 22 but it is not associated with Australia antigen.
Discussion
The current study was performed to test the hypothesis that subtle abnormalities in hepatic function might be detected in patients with Down's syndrome and Au(l). The experimental design is based on a comparative matched pairs technic. It involves matching each individual in the study group with an individual in the control group for pertinent characteristics (i.e., age, sex, race, etc.), and testing the null hypothesis that there is no difference between the two. When the null hypothesis is true, differences between the individuals will be in one direction for some pairs and in the other direction for others. When differences are largely in one direction (the number and degree of which can be calculated), the null hypothesis can be excluded. This technic does not depend on assuming a normal distribution of values.
The results indicate that the presence of Australia antigen in patients with Down's syndrome signifies a persistent active or subacute hepatitis. Au(l) occurs commonly in institutionalized patients with Down's syndrome and, once present, persists for a very long time. In our experience no patient with Down's syndrome with Au(l) has been found to lose the antigen; some patients with Down's syndrome have been followed for 5 yr. (Table 1 ) without disappearance of Au(l). On physical examination, all patients were anicteric and there was no evidence of hepatic disease.
The most consistent finding in the liver chemistries was the slight to moderate elevation of SGPT, suggesting continued activity of inflammatory disease in the liver. SGPT did not generally reach levels considered abnormal in hepatitis; there was only one patient with a median SGPT of more than 100 Karmen units. However, the difference between the SGPT levels of those patients with and without Australia antigen was highly significant (p < 0.005), confirming our previous studies. 20 From this it appears that the levels usually considered normal for SGPT are too high for the evaluation of chronic anicteric hepatitis of Down's syndrome (and possibly other forms of chronic hepatitis). Our studies ir normal laboratory personnel suggest thai an upper limit of 30 Karmen units is more realistic (mean 15, standard deviation 7.5). liver dysfunction in this study. The difference between SGPT levels in the Australia antigen group and the control group is greater than the difference between SCOT levels when the same groups are compared. This greater sensitivity of SGPT was also found in the evaluation of hepatic abnormalities in lepromatous leprosy.
7
Small but significant differences were also found in other tests related to hepatic function (BSP retention, cephalin flocculation, thymol turbidity, total serum proteins, and serum albumin). Even in the patients with Down's syndrome with Au(I) most of these values would be considered normal by the usual clinical criteria (Table 3) . Nevertheless, the fact that significant differences were found when compared with an appropriate, carefully matched group of control patients indicates biologic importance.
There was no difference in total and direct bilirubin, emphasizing the clinical finding that these patients are not jaundiced. We found that many of: the adolescent patients with Down's syndrome as well as other forms of mental retardation had delayed closure of the epiphyses, so that the alkaline phosphatase could not be considered in itself an indicator of hepatic disease. There was no significant difference in prothrombin times.
We have recently completed liver biopsies on 47 patients with Down's syndrome, 27 with and 20 without Au (1). "lilind" histopathologic examination of the specimens indicated an association of serum Au(l) with histologic abnormalities of the liver.
12
This difference was statistically significant (/; = 0.00024). However, in some instances, Australia antigen was detected in the serum in the presence of what appears to be a histologically normal liver and normal hepatic function studies. Certain individuals may have the capacity to develop a relationship with Au(l) such that the "organism" resides in them, presumably permanently, but the host does not develop disease. We cannot exclude the possibility that some patients with An(l) have an internal derangement of liver cells that cannot be detected by light microscopy and that does not induce abnormal liver chemistries.
There are now reports of Au(l) in patients with Down's syndrome from 10 institutions for the mentally retarded in five countries 1 1 ' 1 4 -1 7 ' 1 9 -0 ' 3 0 ' 3 1 (Table 5 ). In every case in which comparisons were made, the frequency of Au(l) was higher in 
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patients with Down's syndrome than in other mentally retarded patients, although the degree of this difference varies from institution to institution. The overall difference is highly significant when these two groups of patients are compared by the chi-square test (p < 0.001) or for each institution by the sign test (p < 0.002).
The patients with Down's syndrome whom we have studied have not received blood transfusions, and all injections of medication are done with sterile, disposable needles that are not reused. It is difficult to maintain proper sanitary conditions in large institutions because of the behavior of these patients, and it appears likely that there is a nonparenteral fecaloral spread of the virus associated with Au(l). Therefore, it is likely that patients with Down's syndrome serve as a reservoir of hepatitis in institutions for the mentally retarded, where this disease is frequently such a serious problem. The findings suggest that the management of such institutions might be altered in such a way as to discourage the spread of disease. Division into smaller units, relative isolation of patients with Down's syndrome and other maneuvers might be considered. Furthermore, it would be advisable not to employ patients with Down's syndrome as food handlers in institutions or elsewhere, and to interdict their volunteering as blood donors.
Australia antigen persists in patients with other diseases and in members of certain populations in addition to patients with Down's syndrome. These include patients with chronic forms of hepatitis, 13 Au(l) , 7 similar to patients with Down's syndrome. There is no difference between SGPT levels of patients with leukemia with and without Au(l) , 25 but these levels are generally higher than those in a normal control group of people. There is no demonstrable difference in hepatic function between ostensibly normal people with Au(l) on Cebu Island in the Philippines and those without Au(l) from the same population.
7 Thus, we see a spectrum in host response to this presumed virus in these groups of individuals with persistent Australia antigen.
There are several lines of evidence that patients with Down's syndrome exhibit host differences from other mentally retarded patients. Their lymphocytes, cultured in vitro, do not respond as well as those of controls to phytohemagglutinin, as measured by DNA polymerase activity and uptake of tritiated thymidine.
1 yG and yM are elevated in patients with Down's syndrome in large institutions, when compared with outpatients with Down's syndrome. 24 This rise is not seen in other mentally retarded patients. This suggests a peculiar form of response to infectious agents commonly encountered in institutions, possibly predisposing to chronicity. yM levels appear to be lower in patients with Down's syndrome than in other mentally retarded patients.
We have proposed that the persistence of Australia antigen and perhaps chronic infection with other organisms is based on an immunologic defect related to lymphocyte function.
1 -24 If this hypothesis is correct, then patients with Down's syndrome should have an impairment of cellular immune responses. Further investigation of patients with Down's syndrome is in progress to provide further information about the nature of the immunologic defect and mechanisms of host response to infection. Director 
